Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials. At week 48, 64 percent of ...

Feb. 26, 2003 -- Adefovir dipivoxil is effective for the treatment of hepatitis B, according to the results of two studies in the Feb. 27 issue of the New England Journal of Medicine. Neither study ...

May 20, 2005 (Chicago) — Treatment with 10 mg of adefovir dipivoxil for 192 weeks resulted in significant and sustained reductions in hepatitis B virus (HBV) DNA levels, with the majority of patients ...

Adefovir Dipivoxil is an antiviral agent prescribed to treat hepatitis B, a chronic viral infection of the liver in patients 12 years and above. The risk or severity of adverse effects can be ...

Studies have demonstrated the superior efficacy of adding adefovir dipivoxil to existing lamivudine therapy compared with switching to adefovir dipivoxil monotherapy in patients with ...

Learn everything you need to know about Adefovir Dipivoxil-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...

Although lamivudine is an effective treatment for chronic hepatitis B (CHB), HBV can develop lamivudine resistance. In these circumstances, adefovir dipivoxil is often used as an alternative therapy, ...

Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in the most severe form of viral hepatitis. There is no currently approved treatment. We investigated the safety and ...

Adefovir dipivoxil 4.1.8 The assessment report included five randomised controlled trials of adefovir dipivoxil in chronic hepatitis B. Four of the studies were conducted in people with HBeAg-positive ...

Adefovir dipivoxil may be a safe option for treating children with chronic hepatitis B, according to recent study results published online. Maureen M. Jonas, MD, and colleagues from Children’s ...

4.1.1 The Assessment Group found three randomised controlled trials investigating peginterferon alfa-2a in chronic hepatitis B. Two trials were in people with HBeAg-positive chronic hepatitis B, and ...